We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Active ingredient in magic mushrooms reduces anxiety and depression in cancer patients
News

Active ingredient in magic mushrooms reduces anxiety and depression in cancer patients

Active ingredient in magic mushrooms reduces anxiety and depression in cancer patients
News

Active ingredient in magic mushrooms reduces anxiety and depression in cancer patients

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Active ingredient in magic mushrooms reduces anxiety and depression in cancer patients"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

A single dose of psilocybin, the major hallucinogenic component in magic mushrooms, induces long-lasting decreases in anxiety and depression in patients diagnosed with life-threatening cancer according to a new study presented at the annual meeting of the American College of Neuropsychopharmacology that took place Dec. 6-10, 2015 in Hollywood, Florida.


Patients who receive a cancer diagnosis often develop debilitating symptoms of anxiety and depression. Reports from the 1960s and 1970s suggest that hallucinogenic drugs such as LSD may alleviate such symptoms in cancer patients, but the clinical value of hallucinogenic drugs for the treatment of mood disturbances in cancer patients remains unclear.


In this new study, Roland Griffiths and colleagues from the Johns Hopkins University School of Medicine investigated the effects of psilocybin on symptoms of anxiety and depression in individuals diagnosed with life-threatening cancer. Five weeks after receiving a dose of psilocybin sufficiently high to induce changes in perception and mystical-type experiences, patients reported significantly lower levels of anxiety and depression compared with patients that received a low dose of the drug. The positive effects on mood persisted in the patients at 6 month follow-up.


The authors suggest that a single dose of psilocybin may be sufficient to produce enduring decreases in negative mood in patients with a life-threatening cancer.


Note: Material may have been edited for length and content. For further information, please contact the cited source.

American College of Neuropsychopharmacology (ACNP)


ACNP 50th Annual Meeting


Advertisement